MSB 2.03% $1.45 mesoblast limited

With remestemcel not approved for AGvHD, there was no way FDA...

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 130 Posts.
    lightbulb Created with Sketch. 16
    With remestemcel not approved for AGvHD, there was no way FDA were going to approve it for anything else (including Ards) until the outstanding issues are resolved/agreed. It all comes down to the OTAT meeting but my biggest question is what are the timelines from that meeting?

    Is it a month for the OTAT meeting minutes, a couple of months to lodge a request for another FDA meeting, another a couple of months to have the meeting and get the minutes?

    This could easily be another 6-12 months to get an outcome on remestemcel and I'd expect NVS will stay on the sidelines until then.

 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.